Engineered non-erythropoietic EPO analogue. Studied for neuropathic pain, nerve regeneration, and metabolic applications including beta-cell protection in diabetes research.
ARA 290 is a peptide that is designed to activate a specific form of the erythropoietin receptor called the innate repair receptor, without producing the blood-cell-stimulating effects of erythropoietin itself. It has been studied primarily for neuropathic pain, inflammation, and tissue protection. Some human trials have been completed.
Neuropathic Pain Research
ARA 290 has been studied in sarcoidosis patients who have small fiber neuropathy, a painful nerve condition. A phase 2 randomized trial in this population showed improvements in pain scores and corneal nerve fiber density compared to placebo — a meaningful finding in a condition with few good treatments.
Inflammation and Tissue Protection
Preclinical and early clinical work has examined ARA 290 for its anti-inflammatory effects. The innate repair receptor appears to activate protective and repair pathways in tissues rather than the classical inflammatory responses associated with full erythropoietin.
Metabolic Research
Some research has examined whether ARA 290 affects insulin sensitivity and metabolic markers, particularly in contexts where inflammation is driving metabolic dysfunction. Small studies have shown some signals, but this area is at an early stage.
Phase 2 randomized trial in sarcoidosis-associated small fiber neuropathy showed improvements in pain and nerve fiber markers.
Anti-inflammatory effects demonstrated in preclinical and early clinical research.
Some small signals in metabolic parameters in early studies.
Safety profile appears favorable in completed trials, with minimal stimulation of red blood cell production.
ARA 290 has completed only small phase 2 trials. The neuropathy data is promising but comes from a specific patient population (sarcoidosis with small fiber neuropathy), and it is unclear how well results would generalize to other conditions or healthier populations. Larger trials would be needed to confirm efficacy and establish the safety profile more completely. It is not approved for any use.
Erythropoietin is known mainly as the hormone that tells bone marrow to make more red blood cells. But erythropoietin also activates a different receptor complex in other tissues — sometimes called the innate repair receptor — that appears to do very different things: protecting cells, reducing inflammation, and supporting repair. The problem with using full erythropoietin for these purposes is that you'd also be stimulating red blood cell production, which can be problematic. ARA 290 is designed to bind only to the tissue-protective receptor complex without triggering the blood-cell-making effects. This allows researchers to study the tissue and nerve protection aspects separately.
In completed trials, ARA 290 was generally well-tolerated. Importantly, it did not produce meaningful stimulation of red blood cell production, which was a key design goal. Adverse events in trials were mild and comparable to placebo groups. It is not approved for any clinical use and remains investigational.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
4–8mg 3x weekly in human phase 2 trials
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
ARA290, a Non-Erythropoietic EPO Analogue, Reduces Neuropathic Pain in Type 2 Diabetes
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.